BioAlliance ..Jetzt Einsteigen und später Gewinne zählen !!! - 500 Beiträge pro Seite
eröffnet am 17.03.10 13:32:24 von
neuester Beitrag 26.08.10 08:39:46 von
neuester Beitrag 26.08.10 08:39:46 von
Beiträge: 50
ID: 1.156.618
ID: 1.156.618
Aufrufe heute: 0
Gesamt: 2.621
Gesamt: 2.621
Aktive User: 0
ISIN: FR0010095596 · WKN: A0HMXA
0,1193
EUR
-3,24 %
-0,0040 EUR
Letzter Kurs 16:58:16 Lang & Schwarz
Neuigkeiten
06.02.24 · Business Wire (engl.)  |
31.01.24 · Business Wire (engl.) |
28.09.23 · Business Wire (engl.) |
06.07.23 · Business Wire (engl.) |
06.06.23 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 6,4900 | +100,93 | |
| 0,9300 | +54,46 | |
| 0,5102 | +43,23 | |
| 2,3300 | +35,61 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0300 | -14,17 | |
| 2,4000 | -15,49 | |
| 209,50 | -15,63 | |
| 2,3000 | -20,96 | |
| 2,0900 | -40,52 |
Feedback
Hab die Aktie schon mal vorgestellt damals hab ich knapp 100% gewinn gemacht , diesmal ist wesentlich mehr drin .
2 Zulassungen stehen im 2Q 2010 an ,jeweils in USA (Loramyc) und Europa (Setofilm).Für die US-Zulassung erhält BioAlliance 20 Mio$ Milestones von Par Pharma .Im 1H 2010 steht auch eine Partnerschaft in Europa für Loramyc .
Wer ein Solides Investment mit richtig viel Potential sucht der ist hier sehr gut aufgehoben . Ich bin heute wieder eingestiegen schaut einfach auf Börse München .
Lest das unten mal durch ich garantiere euch es lohnt sich . VIEL GLÜCK !
BioAlliance ( BIO.PA)
Marktkap: 65 Mio€
Cash: 14,7 €
Kurs: 5 €
Shares Out: 12,9 M
Präsentation März 2010
http://www.bioalliancepharma.com/eng/content/download/6091/6…
The outlook for 2010
BioAlliance Pharma's forthcoming development milestones are as follows:
* Approval of the NDA for Loramyc® in the United States: Q2 2010.
* Approval of the marketing authorization application for Setofilm® in Europe: Q2 2010.
* An alliance in Europe for Loramyc® and Setofilm®: H1 2010.
* Meetings with the European and American regulatory agencies, in order to define the registration strategy for acyclovir Lauriad®: H1 2010.
* Market launch for Loramyc® in the United States: H2 2010.
* Continuation of ongoing clinical development throughout 2010.
2 Zulassungen stehen im 2Q 2010 an ,jeweils in USA (Loramyc) und Europa (Setofilm).Für die US-Zulassung erhält BioAlliance 20 Mio$ Milestones von Par Pharma .Im 1H 2010 steht auch eine Partnerschaft in Europa für Loramyc .
Wer ein Solides Investment mit richtig viel Potential sucht der ist hier sehr gut aufgehoben . Ich bin heute wieder eingestiegen schaut einfach auf Börse München .
Lest das unten mal durch ich garantiere euch es lohnt sich . VIEL GLÜCK !
BioAlliance ( BIO.PA)
Marktkap: 65 Mio€
Cash: 14,7 €
Kurs: 5 €
Shares Out: 12,9 M
Präsentation März 2010
http://www.bioalliancepharma.com/eng/content/download/6091/6…
The outlook for 2010
BioAlliance Pharma's forthcoming development milestones are as follows:
* Approval of the NDA for Loramyc® in the United States: Q2 2010.
* Approval of the marketing authorization application for Setofilm® in Europe: Q2 2010.
* An alliance in Europe for Loramyc® and Setofilm®: H1 2010.
* Meetings with the European and American regulatory agencies, in order to define the registration strategy for acyclovir Lauriad®: H1 2010.
* Market launch for Loramyc® in the United States: H2 2010.
* Continuation of ongoing clinical development throughout 2010.
Kurssprung wird kommen das 2Q bringt jede menge Überraschungen mit .
Nach Loramyc und Setofilm kommt bald das 3.Produkt auf den Markt !!
Diese Aktie ist ein muß für jedes Depot ..
Breakthrough positive phase III results with acyclovir Lauriad®
Primary and secondary endpoints met – Final results
http://www.bioalliancepharma.com/eng/content/download/5352/5…
Nach Loramyc und Setofilm kommt bald das 3.Produkt auf den Markt !!
Diese Aktie ist ein muß für jedes Depot ..
Breakthrough positive phase III results with acyclovir Lauriad®
Primary and secondary endpoints met – Final results
http://www.bioalliancepharma.com/eng/content/download/5352/5…
Diese Aktie ist ein muß für jedes Depot ..
nur für den,der Geld brauch
nur für den,der Geld brauch
Wer ein bißchen Ahnung von Biotech hat sieht sofort das diese Aktie einfach nur massivst Unterbewertet ist .
"In 2009, we proved our ability to hit ambitious targets", stated Dominique Costantini, BioAlliance Pharma's President and CEO. "Our product portfolio is more attractive than ever, with one product on the market, a second soon to be registered in Europe and a third that has successfully completely its Phase III clinical trial. We can thus present a diversified offering in supportive care and cancer care - an offering that is expanding and gaining in value thanks to the compounds that we have just taken into the clinic. This is a significant parameter for our strategic partners internationally and constitutes a strong asset in our future licensing and alliance strategy. 2010 will be an important year, with the US market launch of Loramyc® and the signature of an alliance in supportive care in Europe. We are also going to discuss and refine our registration strategy for acyclovir Lauriad® with the American and European authorities. We consider it to be one of the cornerstones of our portfolio and a product that could trigger new deals for us”.
"In 2009, we proved our ability to hit ambitious targets", stated Dominique Costantini, BioAlliance Pharma's President and CEO. "Our product portfolio is more attractive than ever, with one product on the market, a second soon to be registered in Europe and a third that has successfully completely its Phase III clinical trial. We can thus present a diversified offering in supportive care and cancer care - an offering that is expanding and gaining in value thanks to the compounds that we have just taken into the clinic. This is a significant parameter for our strategic partners internationally and constitutes a strong asset in our future licensing and alliance strategy. 2010 will be an important year, with the US market launch of Loramyc® and the signature of an alliance in supportive care in Europe. We are also going to discuss and refine our registration strategy for acyclovir Lauriad® with the American and European authorities. We consider it to be one of the cornerstones of our portfolio and a product that could trigger new deals for us”.
Antwort auf Beitrag Nr.: 39.161.539 von BrauchGeld am 17.03.10 18:28:39Bist ja offenbar äußerst überzeugt! (Ich garantiere...; Ist ein muß...)
Aber Merci auf jeden Fall mal für den Hinweis! Klingt wirklich interessant!
Aber Merci auf jeden Fall mal für den Hinweis! Klingt wirklich interessant!
Trading Spotlight
20 Mio$ gibts von Par Pharma bei der Zulassung (90% sicher) von Loramyc in USA das würde den Cashbestand auf ca 31 Mio€ aufbessern .
Dann wäre alles was BioAlliance zu bieten hat nur mit rund 35 Mio€ bewertet !!! IST DAS FAIR ????
Ich bin für 25000€ (KK 5€) eingestiegen das sollte mein Optimismus unterstreichen .
Sobald ich mehr geld hab wird reingepumpt hoffe nur das die noch für rund 5€ zu haben sind .
Dann wäre alles was BioAlliance zu bieten hat nur mit rund 35 Mio€ bewertet !!! IST DAS FAIR ????
Ich bin für 25000€ (KK 5€) eingestiegen das sollte mein Optimismus unterstreichen .
Sobald ich mehr geld hab wird reingepumpt hoffe nur das die noch für rund 5€ zu haben sind .
Sieht aus als wollte BioAlliance nach oben ausbrechen ..
Es geht in langsamen Schritten immer weiter hoch ..Wenn die Zulassung kommt dann knallt es richtisch 
Man muss schon sehr sehr lange suchen um etwas vergleichbar günstiges mit diesen Aussichten zu finden .
Man muss schon sehr sehr lange suchen um etwas vergleichbar günstiges mit diesen Aussichten zu finden .
Und da ist schon die erste Zulassung ..Übrigens die NAchricht ist nachbörslich gekommen
23.03.2010 18:32
Bioalliance Pharma Receives European Approval for Its Second Innovative Product Setofilm®
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced approval for Setofilm® in 16 European countries (by decentralized procedure).
Setofilm®, as a thin film strip, is an anti-emetic drug indicated for the prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children. Thanks to its innovative pharmaceutical form, Setofilm® is the first product of its class to have also obtained this indication in post operative nausea and vomiting in children. Indeed, this fast dissolving film disintegrates without water in few seconds in the mouth and is a product of choice in case of risk of aspiration. It is particularly adapted for patients having difficulties to swallow, namely children or elderly.
"Setofilm® is the second product BioAlliance Pharma has registered in Europe. This represents a significant step in building our portfolio and I warmly congratulate our team on this major achievement", declares Dominique Costantini, President and CEO of BioAlliance Pharma. "Setofilm® represents a major advantage for patients as it meets their needs. In the supportive care area Loramyc® and Setofilm® are very complementary as they both address same frail patients, same prescribers and synergies will be reflected commercially".
In Europe, anti-emetic drugs represent a large segment of cancer supportive care market with sales of nearly €400 million in the five largest markets (IMS Health data, 2009). Ondansetron is the leading drug of its class with a 74% market share as of end 2009.
BioAlliance Pharma has acquired Setofilm® commercialization rights for Europe in 2008 from Applied Pharma Research SA (APR), Switzerland. This product is based on a proprietary oral film strip technology platform developed by APR and Labtec GmbH.
..Übrigens die NAchricht ist nachbörslich gekommen 23.03.2010 18:32
Bioalliance Pharma Receives European Approval for Its Second Innovative Product Setofilm®
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced approval for Setofilm® in 16 European countries (by decentralized procedure).
Setofilm®, as a thin film strip, is an anti-emetic drug indicated for the prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children. Thanks to its innovative pharmaceutical form, Setofilm® is the first product of its class to have also obtained this indication in post operative nausea and vomiting in children. Indeed, this fast dissolving film disintegrates without water in few seconds in the mouth and is a product of choice in case of risk of aspiration. It is particularly adapted for patients having difficulties to swallow, namely children or elderly.
"Setofilm® is the second product BioAlliance Pharma has registered in Europe. This represents a significant step in building our portfolio and I warmly congratulate our team on this major achievement", declares Dominique Costantini, President and CEO of BioAlliance Pharma. "Setofilm® represents a major advantage for patients as it meets their needs. In the supportive care area Loramyc® and Setofilm® are very complementary as they both address same frail patients, same prescribers and synergies will be reflected commercially".
In Europe, anti-emetic drugs represent a large segment of cancer supportive care market with sales of nearly €400 million in the five largest markets (IMS Health data, 2009). Ondansetron is the leading drug of its class with a 74% market share as of end 2009.
BioAlliance Pharma has acquired Setofilm® commercialization rights for Europe in 2008 from Applied Pharma Research SA (APR), Switzerland. This product is based on a proprietary oral film strip technology platform developed by APR and Labtec GmbH.
danke schon mal für den tipp
Antwort auf Beitrag Nr.: 39.200.294 von kockar am 23.03.10 19:53:05Nicht der rede wert ...
-------------------------------------------------
Die Aktie bewegt sich immer noch unterm Radar das sieht man auch am Volumen .Ich sage nur Riesenchance von diesem Niveau aus ..
Ausblick fürs 1H 2010
Zulassung für Loramyc in USA << 20 Mio$ Milestones gibts von Par Pharma
Vermarktungspartner für SetoFilm (EU)
Vermarktungspartner für Loramyc (EU)
Da kommt noch einiges an News ..
-------------------------------------------------
Die Aktie bewegt sich immer noch unterm Radar das sieht man auch am Volumen .Ich sage nur Riesenchance von diesem Niveau aus ..
Ausblick fürs 1H 2010
Zulassung für Loramyc in USA << 20 Mio$ Milestones gibts von Par Pharma
Vermarktungspartner für SetoFilm (EU)
Vermarktungspartner für Loramyc (EU)
Da kommt noch einiges an News ..
Mit der Zulassung von Loramyc bräuchte Bioalliance nie mehr eine K.E .BioAlliance hat eine grandiose Zukunft vor sich ..
Und es geht weiter aufwärts .Die 10€+ werden wir dieses Jahr garantiert wieder sehen ..
Aktie nach wie vor Spottbillig .
Aktie nach wie vor Spottbillig .
Wieder Top-News nachbörslich für BioAlliance
Diesmal erhält Loramyc die Zulassungen in 13 weitere EU-Länder !!!!
http://finance.yahoo.com/news/BioAlliance-Pharma-Announces-b…
BioAlliance Pharma Announces Extension of Loramyc® Approval in 13 European Countries
It is Bringing Total European Approvals to 26 European Countries
Press Release Source: BioAlliance On Thursday March 25, 2010, 1:55 pm EDT
PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced today the approval of Loramyc® in 13 additional European countries* through a Mutual Recognition Procedure with France as reference member state.
With this approval to a total of 26 European countries for Loramyc® and the recent Setofilm® ** approval in 16 European countries, BioAlliance is building an attractive cancer supportive care portfolio including this two complementary products.
“These remarkable achievements for both Loramyc® and Setofilm® demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
Diesmal erhält Loramyc die Zulassungen in 13 weitere EU-Länder !!!!
http://finance.yahoo.com/news/BioAlliance-Pharma-Announces-b…
BioAlliance Pharma Announces Extension of Loramyc® Approval in 13 European Countries
It is Bringing Total European Approvals to 26 European Countries
Press Release Source: BioAlliance On Thursday March 25, 2010, 1:55 pm EDT
PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced today the approval of Loramyc® in 13 additional European countries* through a Mutual Recognition Procedure with France as reference member state.
With this approval to a total of 26 European countries for Loramyc® and the recent Setofilm® ** approval in 16 European countries, BioAlliance is building an attractive cancer supportive care portfolio including this two complementary products.
“These remarkable achievements for both Loramyc® and Setofilm® demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
Nochmal zur Unterbewertung von BioAlliance
Aktuelle Marktkap 72 Mio€
Partnerschaft für Setofilm und Loramyc könnte zusammen ca 30-40 Mio€ Upfront einbringen und das nur für Europa !!!
Dann haben wir noch die US-Zulassung für Loramyc das bringt zusätzliche 25 Mio$ Milestone.
Plus Cashbestand von 14 Mio€ wenn mal alles zusammen rechnet kommt man ca auf die höhe der Marktkap das bedeutet Cashbestand wäre so hoch wie die Marktkapitalisierung .
Und das alles soll noch im 1H 2010 stattfinden was besseres wird ma kaum finden .
Aktuelle Marktkap 72 Mio€
Partnerschaft für Setofilm und Loramyc könnte zusammen ca 30-40 Mio€ Upfront einbringen und das nur für Europa !!!
Dann haben wir noch die US-Zulassung für Loramyc das bringt zusätzliche 25 Mio$ Milestone.
Plus Cashbestand von 14 Mio€ wenn mal alles zusammen rechnet kommt man ca auf die höhe der Marktkap das bedeutet Cashbestand wäre so hoch wie die Marktkapitalisierung .
Und das alles soll noch im 1H 2010 stattfinden was besseres wird ma kaum finden .
BioAlliance ist definitiv eines der besten Investment im Biotech Sektor billiger und besser gehts kaum .
Loramyc® <<< ZUGELASSEN IN EU UND SÜDKOREA (MARKTEINFÜHRUNG BISHER IN NUR 5 EU-LÄNDER UND SÜDKOREA) PARTNERSCHAFT FÜR EU IN 2Q 2010 US-ZULASSUNG IN 2Q 2010
•NDA submission and acceptance for Loramyc®in the USA
•Loramyc®: strong commercial dynamic in France with sales at 2.1€over doubled compared to 2008 figure
•Strong hospital-based oncologists referenced product
•Very good safety profile: a significant advantage for other portfolio products based on adhesive Lauriad®technology
•Target market 300M€
Setofilm®: at registration in Europe << KÜRZLICH ZUGELASSEN,PARTNERSCHAFT FÜR EU in 2Q 2010
•Decentralizedprocedure in 16 countries
•Leading compound in antiemetic market
•Indications : patients with chemo and radiotherapy CINV-RINV-PONV
•Main medical interest for patients with difficulties to swallow or risk of aspiration
•Commercial synergies with Loramyc®
•Target market in EU: 400 M€
Acyclovir Lauriad®main advantages << ZULASSUNGSANTRÄGE + PARTNERSCHAFTEN FÜR USA/EU IN 2H 2010
•Single application
•Low dose
•Prevention of vesicularlesionwhenappliedatprodromalstage
•Rapid pain alleviation
•Well tolerated (no local irritation)
•No compliance issues
•Well accepted
•Reduced incidence of and delayed recurrenceInternational pivotal phase III completed Q3 09: complete positive results allowing for a constructive dialog with regulatory agencies
Target market:1 billion $
Und die Pipeline hat noch einiges mehr zu bieten darunter auch Blockbuster ...
Loramyc® <<< ZUGELASSEN IN EU UND SÜDKOREA (MARKTEINFÜHRUNG BISHER IN NUR 5 EU-LÄNDER UND SÜDKOREA) PARTNERSCHAFT FÜR EU IN 2Q 2010 US-ZULASSUNG IN 2Q 2010
•NDA submission and acceptance for Loramyc®in the USA
•Loramyc®: strong commercial dynamic in France with sales at 2.1€over doubled compared to 2008 figure
•Strong hospital-based oncologists referenced product
•Very good safety profile: a significant advantage for other portfolio products based on adhesive Lauriad®technology
•Target market 300M€
Setofilm®: at registration in Europe << KÜRZLICH ZUGELASSEN,PARTNERSCHAFT FÜR EU in 2Q 2010
•Decentralizedprocedure in 16 countries
•Leading compound in antiemetic market
•Indications : patients with chemo and radiotherapy CINV-RINV-PONV
•Main medical interest for patients with difficulties to swallow or risk of aspiration
•Commercial synergies with Loramyc®
•Target market in EU: 400 M€
Acyclovir Lauriad®main advantages << ZULASSUNGSANTRÄGE + PARTNERSCHAFTEN FÜR USA/EU IN 2H 2010
•Single application
•Low dose
•Prevention of vesicularlesionwhenappliedatprodromalstage
•Rapid pain alleviation
•Well tolerated (no local irritation)
•No compliance issues
•Well accepted
•Reduced incidence of and delayed recurrenceInternational pivotal phase III completed Q3 09: complete positive results allowing for a constructive dialog with regulatory agencies
Target market:1 billion $
Und die Pipeline hat noch einiges mehr zu bieten darunter auch Blockbuster ...
Super News
Partner Deal für SetoFilm und Loramyc ist abgeschlossen .Wer hier nicht dabei ist ,ist selbst schuld die Aktie hat riesiges Potential und das bei fast 0 Risiko !
A STRONG BUY AGGRESSIVE AT THIS PRICE << WIE DIE AMIS SAGEN !!
Ausblick für 2010
US-Zulassung für Loramyc 2Q ( 20 Mio$ winken bei FDA OK)
Zulassungsantrag für A.Lauriad in US und EU + Partnerschaften
BioAlliance Pharma Announces Licensing of European Commercialization Rights for Loramyc® and Setofilm® to the Therabel Group in a 48.5 Million Deal
BioAlliance is now relying on partnerships to insure its growth strategy
http://finance.yahoo.com/news/BioAlliance-Pharma-Announces-b…
Partner Deal für SetoFilm und Loramyc ist abgeschlossen .Wer hier nicht dabei ist ,ist selbst schuld die Aktie hat riesiges Potential und das bei fast 0 Risiko !
A STRONG BUY AGGRESSIVE AT THIS PRICE << WIE DIE AMIS SAGEN !!
Ausblick für 2010
US-Zulassung für Loramyc 2Q ( 20 Mio$ winken bei FDA OK)
Zulassungsantrag für A.Lauriad in US und EU + Partnerschaften
BioAlliance Pharma Announces Licensing of European Commercialization Rights for Loramyc® and Setofilm® to the Therabel Group in a 48.5 Million Deal
BioAlliance is now relying on partnerships to insure its growth strategy
http://finance.yahoo.com/news/BioAlliance-Pharma-Announces-b…
Erste Kaufempfehlung mit kursziel 10€ was eine Marktkap von lediglich 129 M€ bedeuten würde ..Mein Kursziel ist das doppelte 20€+ für die nächsten 2 Jahre !
http://www.tradingsat.com/actu-bourse-147342-BIO.html
Suite à cette annonce, CM-CIC Securities a confirmé ce matin son opinion "Achat" et son objectif de cours de 10 euros sur BioAlliance. Le broker estime que l'accord valide le modèle de développement économique de la société biopharmaceutique, tout en sécurisant sa position de trésorerie.
http://www.tradingsat.com/actu-bourse-147342-BIO.html
Suite à cette annonce, CM-CIC Securities a confirmé ce matin son opinion "Achat" et son objectif de cours de 10 euros sur BioAlliance. Le broker estime que l'accord valide le modèle de développement économique de la société biopharmaceutique, tout en sécurisant sa position de trésorerie.
BioAlliance = Super First Class Investment !!!
12 April 2010
Smallcap Event - Paris, France, 12 - 13 April 2010
22 April 2010
Annual General Meeting - Company's head office, Paris, France
12 April 2010
Smallcap Event - Paris, France, 12 - 13 April 2010
22 April 2010
Annual General Meeting - Company's head office, Paris, France
Antwort auf Beitrag Nr.: 39.280.847 von BrauchGeld am 06.04.10 17:14:18schön
Vielleicht sehen wir heute ein neues 52W Hoch ....
Heute und Morgen trifft sich das Management mit einigen Gross-Investoren da könnte der eine oder andere bestimmt von BioAlliance begeistert sein .
BioAlliance Pharma announces participation in the SmallCap Event
On April 12th and 13th in Paris
Paris, March 29, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will participate in the SmallCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 12th and Tuesday 13th of April in Paris (Salons Hoche – 9, avenue Hoche).
During these two days, the Management will meet with institutional investors to present BioAlliance Pharma and its development strategy.
BioAlliance Pharma announces participation in the SmallCap Event
On April 12th and 13th in Paris
Paris, March 29, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will participate in the SmallCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 12th and Tuesday 13th of April in Paris (Salons Hoche – 9, avenue Hoche).
During these two days, the Management will meet with institutional investors to present BioAlliance Pharma and its development strategy.
Gleich knacken wir die 6€ dann dürfte es zügig richtung 7€ gehen .
Ich würde mal sagen die letzte Chance nochmal billig einzusteigen bevor die US-Zulassung kommt !!!
Gleich passiert es wenn nicht heute dann morgen ..
Nach einer kleinen Pause wird die Reise nach oben weiter gehen und umso näher die Zulassung rückt umso schneller wird BIO.PA steigen ..
Marktkap : 79 M€
Cash : 21 M€ <<< Bald kommen noch 20 M$ Milestone dazu !!
Kurs: 6,05 €
Loramyc in Europa und Südkorea Zugelassen und Verpartnert
" US Zulassung im 2Q
SetoFilm in Europa Zugelassen und Verpartnert
Und noch ein Produkt das in Frankreich mit Lundbeck vermarktet wird
BioAlliance Pharma signs a co-promotion agreement with Lundbeck for in-hospital prescription of the antidepressant Seroplex® (PDF - 72 Ko)
Es stehen noch viele Kurstreibende News für 2010 an !!!
Marktkap : 79 M€
Cash : 21 M€ <<< Bald kommen noch 20 M$ Milestone dazu !!
Kurs: 6,05 €
Loramyc in Europa und Südkorea Zugelassen und Verpartnert
" US Zulassung im 2Q
SetoFilm in Europa Zugelassen und Verpartnert
Und noch ein Produkt das in Frankreich mit Lundbeck vermarktet wird
BioAlliance Pharma signs a co-promotion agreement with Lundbeck for in-hospital prescription of the antidepressant Seroplex® (PDF - 72 Ko)
Es stehen noch viele Kurstreibende News für 2010 an !!!
RALLLYYYYYYYYYYYYYY
BioAlliance gehört über 10€ und das wird sowieso bald passieren ..
Es geht richtung Tageshoch ..
Und hier die nächste FDA-Zulassung (gibt es als PDF auf der Bioalliance-Webseite):
(http://www.bioalliancepharma.com/eng/content/download/6447/7…)
BioAlliance Pharma gains US FDA approval for Oravig® (Loramyc® in EU)
And is eligible for a $20 million milestone payment
from Strativa Pharmaceuticals, its commercial partner in the US
Paris, April 16, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA (Food and Drug Administration) of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.
Oravig® is licensed to Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. and will be launched in the course of this second semester. The license agreement signed in July 2007 contemplates a $20 million milestone payment upon FDA approval, additional sales milestones and royalties on sales of the product.
“This is a major achievement and the first time for a French biotech company to gain a US approval. BioAlliance expertise in development and registration at the international level is here properly recognized and rewarded. Following our commercial partnership agreement with Therabel Group for Europe (Loramyc® and Setofilm®), we are very confident in Strativa’s commercialization ability to ensure Oravig® success in the US”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
“With Oravig®, BioAlliance has developed an innovative local treatment for oral candida infection. We are very proud to now bring Oravig® to health care providers and patients in the US”, added John Mac Phee, Strativa President.
The NDA submission was based on the European file and on data from a large Phase III study (577 patients, 28 sites in the United States, Canada, and South Africa) comparing Oravig® (miconazole Lauriad®) to Mycelex® Troche (clotrimazole, the reference product in the USA) in the complete resolution of signs and symptoms of OPC.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
About Strativa Pharmaceuticals
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE PRX), excels at finding, enhancing, and bringing to market drugs that make a meaningful difference to patients. For more information about Strativa, visit www.strativapharma.com.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59 / caroline@alizerp.com
****************
Wenn das mal nicht GUT klingt!
(http://www.bioalliancepharma.com/eng/content/download/6447/7…)
BioAlliance Pharma gains US FDA approval for Oravig® (Loramyc® in EU)
And is eligible for a $20 million milestone payment
from Strativa Pharmaceuticals, its commercial partner in the US
Paris, April 16, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA (Food and Drug Administration) of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.
Oravig® is licensed to Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. and will be launched in the course of this second semester. The license agreement signed in July 2007 contemplates a $20 million milestone payment upon FDA approval, additional sales milestones and royalties on sales of the product.
“This is a major achievement and the first time for a French biotech company to gain a US approval. BioAlliance expertise in development and registration at the international level is here properly recognized and rewarded. Following our commercial partnership agreement with Therabel Group for Europe (Loramyc® and Setofilm®), we are very confident in Strativa’s commercialization ability to ensure Oravig® success in the US”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
“With Oravig®, BioAlliance has developed an innovative local treatment for oral candida infection. We are very proud to now bring Oravig® to health care providers and patients in the US”, added John Mac Phee, Strativa President.
The NDA submission was based on the European file and on data from a large Phase III study (577 patients, 28 sites in the United States, Canada, and South Africa) comparing Oravig® (miconazole Lauriad®) to Mycelex® Troche (clotrimazole, the reference product in the USA) in the complete resolution of signs and symptoms of OPC.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
About Strativa Pharmaceuticals
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE PRX), excels at finding, enhancing, and bringing to market drugs that make a meaningful difference to patients. For more information about Strativa, visit www.strativapharma.com.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59 / caroline@alizerp.com
****************
Wenn das mal nicht GUT klingt!
Antwort auf Beitrag Nr.: 39.359.451 von alabama76 am 19.04.10 10:17:56Hm, ich schrieb "die nächste FDA-Zulassung". Kann es sein, dass es die ERSTE FDA-Zulassung für Bioalliance ist? Was für die Aktie sicherlich noch besser wäre.
Kleine Erinnerung:
Morgen (22.4.2010) findet die BioAlliance-Hauptversammlung statt. Jedenfalls würde ich "general meeting" (so steht es auf der Webseite) so übersetzen.
Ich bin gespannt.
Morgen (22.4.2010) findet die BioAlliance-Hauptversammlung statt. Jedenfalls würde ich "general meeting" (so steht es auf der Webseite) so übersetzen.
Ich bin gespannt.
Gute Neuigkeiten:
http://www.businesswire.com/portal/site/home/permalink/?ndmV…
BioAlliance Pharma SA: Q1 2010 reflects the new European partnership agreement with Therabel
Expected recurrent revenues
PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated revenue of €6.1 million for the first quarter of 2010 versus €2.6 million in Q1 2009.
Turnover and Cash
The European licensing agreement of Loramyc® and Setofilm®, signed on March 31th 2010 with Therabel, contributes significantly to the quarterly performance. The upfront payment of €4.5 million paid by this new strategic partner is fully recognized as revenue. Revenues from licenses and other agreements previously signed by BioAlliance with Par Pharmaceutical/Strativa, Handok and NovaMed amount to €1 million, corresponding to the installments of the payments received upon signature.
The turnover of the first quarter of 2010 also includes the direct sales of Loramyc® in France for a total amount of €0.6 million, strongly growing compared to the first quarter of 2009 (€0.4 million). The prescriptions of Loramyc® are constantly increasing, with nearly 10.000 additional treated patients during the first quarter and more than 60.000 treated patients since launch. At the time BioAlliance is transferring its commercial operations in France to Therabel Hôpital Pharma, the strong image and the significant role of Loramyc® in the supportive care area in the hospital setting will be a strong synergistic support for the launch of Setofilm® (just approved in 16 European countries). These two products will foster Therabel growth in the European market.
« With partners in Europe, USA and Asia, BioAlliance now has consistent and experienced structures to organize the commercialization of its first two products, Loramyc® and Setofilm®, and to generate a recurring revenue stream», said Dominique Costantini, CEO of BioAlliance Pharma. « From now on, Therabel will be in charge of Loramyc®’s operations in France and will launch this product, together with Setofilm®, in major European countries, once price and reimbursement negotiations are completed. Par/Strativa is expected to launch Loramyc® on the US market during the second half of the year, under the brand name Oravig® ».
« BioAlliance Pharma’s cash reserves are significantly reinforced by the partnership agreement with Therabel and the expected upfront payment of $20 million from Par Pharmaceutical upon approval of Oravig® in the United States, obtained on April 16th 2010 », adds Nicolas Fellmann, Chief Financial Officer. « As of March 31, thanks to these elements and to the expected reimbursement of the 2009 research tax credit of €1.8 million, the Company has a visibility of nearly two years to finance its projects and its growth, not taking into account potential new license agreements on other portfolio products ».
Recent achievements
During the first quarter, significant progress has been achieved for the products of the portfolio:
* With 13 additional approvals, Loramyc® is now registered in 26 European countries,
* The second product, Setofilm®, has been approved in 16 European countries,
* A first clinical phase I trial of fentanyl Lauriad® in chronic cancer pain has confirmed the systemic absorption of fentanyl in healthy volunteers.
In addition, the company is pursuing the clinical development of three promising products in the areas of supportive care and severe and orphan cancers: clonidine Lauriad® in mucositis, doxorubicin Transdrug® nanoparticles in primary liver cancer and AMEPTM, a biotherapy in metastatic melanoma. Besides, based on the phase III positive final results for acyclovir Lauriad®, BioAlliance is discussing its registration strategy with the Agencies.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
http://www.businesswire.com/portal/site/home/permalink/?ndmV…
BioAlliance Pharma SA: Q1 2010 reflects the new European partnership agreement with Therabel
Expected recurrent revenues
PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated revenue of €6.1 million for the first quarter of 2010 versus €2.6 million in Q1 2009.
Turnover and Cash
The European licensing agreement of Loramyc® and Setofilm®, signed on March 31th 2010 with Therabel, contributes significantly to the quarterly performance. The upfront payment of €4.5 million paid by this new strategic partner is fully recognized as revenue. Revenues from licenses and other agreements previously signed by BioAlliance with Par Pharmaceutical/Strativa, Handok and NovaMed amount to €1 million, corresponding to the installments of the payments received upon signature.
The turnover of the first quarter of 2010 also includes the direct sales of Loramyc® in France for a total amount of €0.6 million, strongly growing compared to the first quarter of 2009 (€0.4 million). The prescriptions of Loramyc® are constantly increasing, with nearly 10.000 additional treated patients during the first quarter and more than 60.000 treated patients since launch. At the time BioAlliance is transferring its commercial operations in France to Therabel Hôpital Pharma, the strong image and the significant role of Loramyc® in the supportive care area in the hospital setting will be a strong synergistic support for the launch of Setofilm® (just approved in 16 European countries). These two products will foster Therabel growth in the European market.
« With partners in Europe, USA and Asia, BioAlliance now has consistent and experienced structures to organize the commercialization of its first two products, Loramyc® and Setofilm®, and to generate a recurring revenue stream», said Dominique Costantini, CEO of BioAlliance Pharma. « From now on, Therabel will be in charge of Loramyc®’s operations in France and will launch this product, together with Setofilm®, in major European countries, once price and reimbursement negotiations are completed. Par/Strativa is expected to launch Loramyc® on the US market during the second half of the year, under the brand name Oravig® ».
« BioAlliance Pharma’s cash reserves are significantly reinforced by the partnership agreement with Therabel and the expected upfront payment of $20 million from Par Pharmaceutical upon approval of Oravig® in the United States, obtained on April 16th 2010 », adds Nicolas Fellmann, Chief Financial Officer. « As of March 31, thanks to these elements and to the expected reimbursement of the 2009 research tax credit of €1.8 million, the Company has a visibility of nearly two years to finance its projects and its growth, not taking into account potential new license agreements on other portfolio products ».
Recent achievements
During the first quarter, significant progress has been achieved for the products of the portfolio:
* With 13 additional approvals, Loramyc® is now registered in 26 European countries,
* The second product, Setofilm®, has been approved in 16 European countries,
* A first clinical phase I trial of fentanyl Lauriad® in chronic cancer pain has confirmed the systemic absorption of fentanyl in healthy volunteers.
In addition, the company is pursuing the clinical development of three promising products in the areas of supportive care and severe and orphan cancers: clonidine Lauriad® in mucositis, doxorubicin Transdrug® nanoparticles in primary liver cancer and AMEPTM, a biotherapy in metastatic melanoma. Besides, based on the phase III positive final results for acyclovir Lauriad®, BioAlliance is discussing its registration strategy with the Agencies.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
Danke alabama
Weitere kommende News für 2010
EU und US Zulassungsantrag für Acyclovir Lauriad
EU und US Partnerschaften für Acyclovir Lauriad
Marktkap: 80 Mio€
Kurs: 6,50€
Shares Out : 12,9
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
Weitere kommende News für 2010
EU und US Zulassungsantrag für Acyclovir Lauriad
EU und US Partnerschaften für Acyclovir Lauriad
Marktkap: 80 Mio€
Kurs: 6,50€
Shares Out : 12,9
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
Equity investment by Therabel
and transition from a Supervisory Board to a Board of Directors
Paris, April 26, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that Therabel has taken an equity stake in BioAlliance, according to the European licence agreement for Loramyc® and Setofilm® signed on March 31st 2010. Furthermore, the General Assembly Meeting, held on April 22, 2010, has adopted all the proposed resolutions, notably the change in the BioAlliance governance mode from a Supervisory Board to a Board of Directors.
This Board of Directors (composed of 8 members including 5 from the previous Supervisory Board) has appointed as planned a non executive Chairman, André Ulmann, who will also chair the Compensation Committee, in its meeting held immediately following the General Assembly. Dominique Costantini has been appointed Chief Executive Officer and Gilles Avenard Deputy Chief Executive Officer. The other independent members are Michel Arié, also Chairman of the Audit Committee, Gilles Marrache and Catherine Dunand*, new Board member. The Board also includes two shareholder representatives, ING Belgique represented by Denis Biju-Duval and AGF Private Equity represented by Rémi Droller.
“We are delighted with this equity investment by Therabel. This confirms our European strategic partnership which will ensure the commercial success of Loramyc® and Setofilm®, both products registered by BioAlliance Pharma. Therabel thus emphasizes its strategy to invest in the supportive care area in the hospital setting”, said Dominique Costantini, CEO of BioAlliance Pharma.
“This evolution of the Board allows us to be more reactive today. We would like to thank both leaving members of the Supervisory Board, Jean-Marie Zacharie and François Sarkozy. For many years they brought to the company their great professional experience. We are extremely glad of the diversity of this new Board of Directors which includes leading managers, shareholders’ representatives and independent members bringing their knowledge and expertise to the Company”, she added. “We wish to thank warmly our shareholders for their support in these major steps”.
*Catherine Dunand
Board member of Altavia group (communication and marketing group), she has been managing SMEs for 10 years, in a context of LBO in the health and communication areas. Previously, she held international management responsibilities in the pharmaceutical industry (Hoechst Roussel, Servier).
Catherine Dunand graduated from Ecole Centrale of Lyon and holds a MBA from INSEAD.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59 / caroline@alizerp.com
and transition from a Supervisory Board to a Board of Directors
Paris, April 26, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that Therabel has taken an equity stake in BioAlliance, according to the European licence agreement for Loramyc® and Setofilm® signed on March 31st 2010. Furthermore, the General Assembly Meeting, held on April 22, 2010, has adopted all the proposed resolutions, notably the change in the BioAlliance governance mode from a Supervisory Board to a Board of Directors.
This Board of Directors (composed of 8 members including 5 from the previous Supervisory Board) has appointed as planned a non executive Chairman, André Ulmann, who will also chair the Compensation Committee, in its meeting held immediately following the General Assembly. Dominique Costantini has been appointed Chief Executive Officer and Gilles Avenard Deputy Chief Executive Officer. The other independent members are Michel Arié, also Chairman of the Audit Committee, Gilles Marrache and Catherine Dunand*, new Board member. The Board also includes two shareholder representatives, ING Belgique represented by Denis Biju-Duval and AGF Private Equity represented by Rémi Droller.
“We are delighted with this equity investment by Therabel. This confirms our European strategic partnership which will ensure the commercial success of Loramyc® and Setofilm®, both products registered by BioAlliance Pharma. Therabel thus emphasizes its strategy to invest in the supportive care area in the hospital setting”, said Dominique Costantini, CEO of BioAlliance Pharma.
“This evolution of the Board allows us to be more reactive today. We would like to thank both leaving members of the Supervisory Board, Jean-Marie Zacharie and François Sarkozy. For many years they brought to the company their great professional experience. We are extremely glad of the diversity of this new Board of Directors which includes leading managers, shareholders’ representatives and independent members bringing their knowledge and expertise to the Company”, she added. “We wish to thank warmly our shareholders for their support in these major steps”.
*Catherine Dunand
Board member of Altavia group (communication and marketing group), she has been managing SMEs for 10 years, in a context of LBO in the health and communication areas. Previously, she held international management responsibilities in the pharmaceutical industry (Hoechst Roussel, Servier).
Catherine Dunand graduated from Ecole Centrale of Lyon and holds a MBA from INSEAD.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59 / caroline@alizerp.com
Unser umtriebiges BioAlliance kündigte gestern (30.4.2010) seine Teilnahme an drei großen internationalen Veranstaltungen im Mai an:
Quelle: http://www.bioalliancepharma.com/eng/content/download/6588/7… (PDF-Pressemitteilung)
BioAlliance Pharma announces participation in three major international events in May 2010
Paris, April 30, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that it will participate in the following international events:
- - -
BIO International Convention 2010 – Chicago, Illinois USA – May 3 to 6, 2010,
London European Midcap Event – London, UK – May 11 & 12, 2010,
BioEquity Europe 2010 – Zurich, Switzerland – May 19 & 20, 2010.
During these conferences, the Management of BioAlliance Pharma will present the recent achievements, the growth strategy and the perspectives of the company.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries Acyclovir Lauriad® (Labialis herpes): Positive phase III final results Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results AMEPTM (Invasive melanoma): Phase I Clonidine Lauriad® (Mucositis): Phase II Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
--------
Klingt sehr schön in meinen Augen.
I like it.
Quelle: http://www.bioalliancepharma.com/eng/content/download/6588/7… (PDF-Pressemitteilung)
BioAlliance Pharma announces participation in three major international events in May 2010
Paris, April 30, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that it will participate in the following international events:
- - -
BIO International Convention 2010 – Chicago, Illinois USA – May 3 to 6, 2010,
London European Midcap Event – London, UK – May 11 & 12, 2010,
BioEquity Europe 2010 – Zurich, Switzerland – May 19 & 20, 2010.
During these conferences, the Management of BioAlliance Pharma will present the recent achievements, the growth strategy and the perspectives of the company.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries Acyclovir Lauriad® (Labialis herpes): Positive phase III final results Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results AMEPTM (Invasive melanoma): Phase I Clonidine Lauriad® (Mucositis): Phase II Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
--------
Klingt sehr schön in meinen Augen.
I like it.
Im Augenblick weiß ich nicht, ob ich von der Kursentwicklung enttäuscht sein soll oder mich freuen soll, dass ich heute zu meinem Einstiegspreis von 5,35 EUR nochmal nachkaufen könnte.
Was meint ihr? Gibt's einen Grund für den Kursschwund?
Was meint ihr? Gibt's einen Grund für den Kursschwund?
Antwort auf Beitrag Nr.: 39.489.520 von BrauchGeld am 10.05.10 09:25:27
BioAlliance hat 2 Produkte am Markt das dritte wird innerhalb 12-15 Monate dazu kommen weitere Partnerschaften sind auch in Anmarsch usw. = SUPER ATTRAKTIVES INVESTMENT !!!
Marktkap : 72 Mio€
Gigantische Pipeline
BioAlliance hat 2 Produkte am Markt das dritte wird innerhalb 12-15 Monate dazu kommen weitere Partnerschaften sind auch in Anmarsch usw. = SUPER ATTRAKTIVES INVESTMENT !!!
Marktkap : 72 Mio€
Gigantische Pipeline
BioAlliance hat gerade die Ergebnisse der präklinischen Studie seiner Therapie für Melanome präsentiert.
Der Text stammt aus der BioAlliance-Presseveröffentlichung, die ihr hier abrufen könnt:
Sehr gute Nachrichten:
http://www.bioalliancepharma.com/eng/content/download/6734/7… (PDF)
BioAlliance Pharma presents preclinical results for
its AMEP™ biotherapy in the treatment of invasive melanoma supporting ongoing phase I clinical trial
13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
(Washington DC, May 17- 22, 2010)
Paris, May 25, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGT) in Washington, DC (May 17 – 22, 2010).
The AMEP™ biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins) involved in tumor growth and in tumor angiogenesis.
The results presented at the ASGT demonstrated regulatory preclinical efficacy and safety:
Efficacy studies demonstrated that AMEPTM administration in human melanoma xenograft models induced a higher tumor growth inhibition than with Temozolomide, the standard chemotherapy used in metastatic melanoma treatment ;
Safety and biodistribution studies showed a good overall tolerance with AMEP™ and a progressive elimination from tissues without accumulation.
Based on these results, AMEP™ phase I clinical trial has been initiated for the treatment of advanced and metastatic melanoma in France, Denmark and Slovenia.
BioAlliance has been granted €6.4 million from OSEO (the French state innovation agency) which finances technological breakthrough projects.
About the American Society of Gene & Cell Therapy (ASGCT)
The ASCGT is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. ASGCT includes researchers, clinicians, and other professionals from around the world dedicated to discovering and developing new genetic and cellular therapies.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
Der Text stammt aus der BioAlliance-Presseveröffentlichung, die ihr hier abrufen könnt:
Sehr gute Nachrichten:
http://www.bioalliancepharma.com/eng/content/download/6734/7… (PDF)
BioAlliance Pharma presents preclinical results for
its AMEP™ biotherapy in the treatment of invasive melanoma supporting ongoing phase I clinical trial
13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
(Washington DC, May 17- 22, 2010)
Paris, May 25, 2010 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGT) in Washington, DC (May 17 – 22, 2010).
The AMEP™ biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins) involved in tumor growth and in tumor angiogenesis.
The results presented at the ASGT demonstrated regulatory preclinical efficacy and safety:
Efficacy studies demonstrated that AMEPTM administration in human melanoma xenograft models induced a higher tumor growth inhibition than with Temozolomide, the standard chemotherapy used in metastatic melanoma treatment ;
Safety and biodistribution studies showed a good overall tolerance with AMEP™ and a progressive elimination from tissues without accumulation.
Based on these results, AMEP™ phase I clinical trial has been initiated for the treatment of advanced and metastatic melanoma in France, Denmark and Slovenia.
BioAlliance has been granted €6.4 million from OSEO (the French state innovation agency) which finances technological breakthrough projects.
About the American Society of Gene & Cell Therapy (ASGCT)
The ASCGT is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. ASGCT includes researchers, clinicians, and other professionals from around the world dedicated to discovering and developing new genetic and cellular therapies.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEPTM (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
Ich verstehe nicht, wie sie nach all den guten News und Zulassungen wieder bis auf 5,00 Euro fällt. Hat von euch jemand ne Erklärung dafür?
22.07.2010
BioAlliance Pharma SA: A Record Turnover for Q2 2010 Reflecting the Successful US FDA Approval
Regulatory News:
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a turnover of €15.2 million for the second quarter of 2010 versus €1.5 million in Q2 2009.
Turnover and Cash
This dramatic increase is directly linked to the successful approval of Loramyc® in the US under the brand name Oravig™ in April 2010, and upon which BioAlliance has received a $20 million milestone payment from its commercial partner, Strativa Pharmaceuticals, fully recognized as revenue (€14.8 million).
"The US approval of OravigTM is a major step for BioAlliance Pharma that reflects the expertise of its teams”, declares Dominique Costantini, CEO of BioAlliance Pharma. "We are the only small and medium-sized innovative French Company to have a drug approved on the US market, the largest market worldwide. Our US partner, Strativa Pharmaceuticals, is actively preparing the launch of OravigTM after the summer. BioAlliance has now some advanced products capable to generate global revenues and long-lasting growth”.
Beside this significant achievement, income from licensing agreements totaled €0.3 million. This includes notably royalties from Therabel on Loramyc® sales in France and the first supply of OravigTM to the US partner, Strativa Pharmaceuticals.
BioAlliance Pharma cash reserves have been reinforced by the payments received from Therabel in March (for a total of €7.5 million) and from Strativa Pharmaceuticals in April (€14.8 million) and thus amount up to €28.9 million as of June 30, 2010. This total includes the reimbursement of the 2009 research tax credit of €1.8 million received in May. "This increase in our cash reserves, with non-dilutive revenues from our licensing agreements, demonstrates the relevance of our strategic options, and allows us to fund our growth based on our product portfolio”, underlines Nicolas Fellmann, Chief Financial Officer of BioAlliance Pharma.
Recent achievements
During the second quarter, BioAlliance Pharma has carried on discussions with Health Authorities and is planning the European registration file submission of acyclovir Lauriad® in mid-2011, based on the final positive results of its pivotal phase III clinical trial including more than 700 patients. In addition, the Company is pursuing the clinical development of three promising products in the areas of supportive care and orphan cancers: clonidine Lauriad® in radio- and chemo-induced oral mucositis, fentanyl Lauriad® in cancer chronic pain and AMEP®, a biotherapy in metastatic melanoma.
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance (Paris:BIO) conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEP® (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA: A Record Turnover for Q2 2010 Reflecting the Successful US FDA Approval
Regulatory News:
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a turnover of €15.2 million for the second quarter of 2010 versus €1.5 million in Q2 2009.
Turnover and Cash
This dramatic increase is directly linked to the successful approval of Loramyc® in the US under the brand name Oravig™ in April 2010, and upon which BioAlliance has received a $20 million milestone payment from its commercial partner, Strativa Pharmaceuticals, fully recognized as revenue (€14.8 million).
"The US approval of OravigTM is a major step for BioAlliance Pharma that reflects the expertise of its teams”, declares Dominique Costantini, CEO of BioAlliance Pharma. "We are the only small and medium-sized innovative French Company to have a drug approved on the US market, the largest market worldwide. Our US partner, Strativa Pharmaceuticals, is actively preparing the launch of OravigTM after the summer. BioAlliance has now some advanced products capable to generate global revenues and long-lasting growth”.
Beside this significant achievement, income from licensing agreements totaled €0.3 million. This includes notably royalties from Therabel on Loramyc® sales in France and the first supply of OravigTM to the US partner, Strativa Pharmaceuticals.
BioAlliance Pharma cash reserves have been reinforced by the payments received from Therabel in March (for a total of €7.5 million) and from Strativa Pharmaceuticals in April (€14.8 million) and thus amount up to €28.9 million as of June 30, 2010. This total includes the reimbursement of the 2009 research tax credit of €1.8 million received in May. "This increase in our cash reserves, with non-dilutive revenues from our licensing agreements, demonstrates the relevance of our strategic options, and allows us to fund our growth based on our product portfolio”, underlines Nicolas Fellmann, Chief Financial Officer of BioAlliance Pharma.
Recent achievements
During the second quarter, BioAlliance Pharma has carried on discussions with Health Authorities and is planning the European registration file submission of acyclovir Lauriad® in mid-2011, based on the final positive results of its pivotal phase III clinical trial including more than 700 patients. In addition, the Company is pursuing the clinical development of three promising products in the areas of supportive care and orphan cancers: clonidine Lauriad® in radio- and chemo-induced oral mucositis, fentanyl Lauriad® in cancer chronic pain and AMEP®, a biotherapy in metastatic melanoma.
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance (Paris:BIO) conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEP® (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
!
Dieser Beitrag wurde moderiert. Grund: Postings von Doppel-IDs
Paris, 4. August 2010
- BioAlliance Pharma SA (Euronext Paris - BIO), ein Unternehmen spezialisiert auf traitement du cancer et aux soins de support, annonce aujourd'hui que M. Gilles Avenard a Krebsbehandlung und unterstützende Pflege, gab heute bekannt, dass Gilles hat Avenard démissionné de son mandat de Membre du Conseil d'administration et Directeur général Rücktritt als Mitglied des Verwaltungsrates und CEO délégué, en charge de la R&D. Delegierter in Gebühr von R & D. Par ailleurs, le Dr Pierre Attali, en charge des Affaires médicales au sein de BioAlliance Darüber hinaus Dr. Pierre Attali, Leiter des Medical Affairs in BioAlliance depuis plusieurs années, est nommé Directeur général délégué. Seit mehreren Jahren war Chief Operating Officer ernannt. «Je me réjouis de la nomination de Pierre Attali. "Ich begrüße die Ernennung von Pierre Attali. Son expérience du développement au Seine Erfahrung in der Entwicklung niveau international, acquise notamment au sein de Synthélabo, et sa pratique hospitalière internationaler Ebene, einschließlich innerhalb Synthelabo erworben und Krankenhaus-Praxis sont des atouts majeurs pour la société et pour ses partenaires commerciaux dans la sind wichtige Trümpfe für das Unternehmen und seine Handelspartner in der préparation des prochains lancements des produits BioAlliance » , déclare Dominique Vorbereitung künftiger Produkteinführungen BioAlliance ", sagte Dominique Costantini, Directeur général de BioAlliance. « Au nom de toute la Société et du Conseil Costantini, CEO von BioAlliance. "Im Namen der Gesellschaft und des Rates d'administration, je remercie chaleureusement Gilles Avenard pour l'esprit pionnier qu'il a su Administration, ich danke Gilles Avenard für den Pioniergeist, hat insuffler à la société en tant que fondateur et dirigeant, pour sa forte contribution et pour la Infusion das Unternehmen als Gründer und Leiter, für seine starken Beitrag und für mise en place des organisations. Entwicklungsorganisationen. Il a apporté tout au long de ces nombreuses années des Er hat in all diesen Jahren viele innovations qui ont permis à la Société de franchir les étapes clés de son développement. Innovationen, die Entwicklung ihrer aktiviert haben, die von Unternehmen zu überqueren den entscheidenden Phasen. Nous lui souhaitons plein succès dans tous ses projets futurs personnels et professionnels» . Wir wünschen ihm viel Erfolg in seinem persönlichen und beruflichen Zukunft. "
--------------------------------------------------------------------------------
Page 2 Seite 2
A propos de BioAlliance Pharma Über BioAlliance Spécialisée dans le cancer et les soins de support - pathologies associées à la cancérologie, Spezialisiert auf Krebs und die unterstützende Behandlung - Bedingungen im Zusammenhang mit Krebs, complications de la chimiothérapie et de la radiothérapie et infections opportunistes qui se Komplikationen von Chemo-und Strahlentherapie und opportunistische Infektionen, développent chez les patients immunodéprimés - BioAlliance Pharma conçoit et développe des entwickeln, bei immungeschwächten Patienten - BioAlliance entwirft und entwickelt médicaments innovants essentiellement à visée hospitalière et des médicaments dans des maladies innovative Medikamente in erster Linie nach Krankenhaus und Medikamente bei Krankheiten rares ou orphelines. seltene oder Waise. Créée en 1997 et introduite sur le marché d'Euronext Paris en 2005, la société a Gegründet im Jahr 1997 und notiert an der Euronext Paris im Jahr 2005 das Unternehmen pour ambition de devenir un acteur de référence dans ces domaines, en faisant le lien entre Ehrgeiz, um Felder zu einem führenden Player in dieser, Verknüpfen innovation et besoin des patients. Innovation und Bedürfnisse der Patienten. Elle détient des compétences clés pour identifier, développer et Sie hält den Schlüsselkompetenzen zu identifizieren, weiterzuentwickeln und enregistrer des médicaments en Europe et aux Etats-Unis ; elle confie leur commercialisation à un Shop Arzneimitteln in Europa und den Vereinigten Staaten, vertraute sie einer Marketing réseau de partenaires commerciaux internationaux implantés à l'hôpital. Netzwerk von internationalen Handelspartnern Krankenhaus befindet sich in der. Ses approches ciblées dans des domaines où les besoins médicaux sont insuffisamment satisfaits Seine gezielte Ansätze in Bereichen, in denen medizinische Bedürfnisse erfüllt sind unzureichend contribuent à lutter contre les résistances médicamenteuses et à améliorer la santé et la qualité de vie Beitrag zur Bekämpfung der Resistenz und zur Verbesserung des Lebens Gesundheit und Lebensqualität von des patients. Patienten. BioAlliance Pharma a développé un portefeuille de produits avancés : BioAlliance hat Produkte entwickelt, ein Portfolio von Advanced: Loramyc Loramyc ® ® (Candidose oropharyngée chez les patients immunodéprimés) : Enregistré dans 26 pays (Oropharyngeale Candidiasis bei immungeschwächten Patienten): Aufgenommen in 26 Ländern européens, en Corée et aux Etats-Unis Europa, Korea und den Vereinigten Staaten Setofilm Setofilm ® ® (Prévention et traitement des nausées et vomissements induits par la chimiothérapie et la (Vorbeugung und Behandlung von Übelkeit und Erbrechen infolge von Chemotherapie und radiothérapie et en post-opératoire chez l'adulte et l'enfant) : Enregistré dans 16 pays européens postoperative Strahlentherapie und bei Erwachsenen und Kindern): Länder verzeichneten in 16 europäischen Acyclovir Lauriad Acyclovir Lauriad ® ® (Herpès labial) : Phase III positive (résultats finaux) (Herpes labialis): Positive Phase III (endgültige Ergebnisse) Fentanyl Lauriad Fentanyl Lauriad ® ® (Douleur chronique chez le patient cancéreux) : Résultats cliniques préliminaires (Chronische Schmerzen bei Krebspatienten): erste klinische Ergebnisse positifs de la 1ère Phase I Positive Phase I des ersten AMEP AMEP ® ® (Mélanome invasif) : Phase I (Invasive Melanom): Phase I Clonidine Lauriad Clonidin Lauriad ® ® (Mucite post-chimiothérapie et radiothérapie) : Phase II (Mukositis nach Chemo-und Strahlentherapie): Phase II Doxorubicine Transdrug Doxorubicin Transdrug ® ® (Cancer du foie) : Phase II (Leberkrebs): Phase II Pour plus d'informations, visitez le site de BioAlliance Pharm a à www.bioalliancepharma.com Für weitere Informationen, besuchen Sie BioAlliance Pharm hat www.bioalliancepharma.com Avertissement Warnung Le présent communiqué contient de manière implicite ou expresse certaines déclarations prospectives relatives à Diese Pressemitteilung enthält ausdrückliche oder stillschweigende bestimmte zukunftsbezogene Aussagen in Bezug auf BioAlliance Pharma SA et à son activité. BioAlliance Pharma SA und deren Geschäftstätigkeit betreffen. Ces déclarations dépendent de certains risques connus ou non, Diese Aussagen beinhalten bestimmte bekannte und unbekannte Risiken, d'incertitudes, ainsi que d'autres facteurs, qui pourraient conduire à ce que les résultats réels, les conditions Ungewissheiten und andere Faktoren, die Bedingungen, könnte dazu führen, dass die tatsächlichen Ergebnisse financières, les performances ou réalisations de BioAlliance Pharma SA diffèrent significativement des résultats, Finanz-, Leistungen oder Errungenschaften des BioAlliance Pharma SA erheblich von Ergebnissen, conditions financières, performances ou réalisations exprimés ou sous-entendus dans ces déclarations finanziellen Bedingungen, Leistungen oder Errungenschaften explizit oder implizit in diesen Aussagen prospectives. Interessenten. BioAlliance émet ce communiqué à la présente date et ne s'engage pas à mettre à jour les BioAlliance, die diese Mitteilung ab diesem Datum und verpflichtet sich nicht zur Aktualisierung déclarations prospectives qui y sont contenues, que ce soit par suite de nouvelles informations, événements Zukunftsgerichtete Aussagen darin enthalten ist, ob als Ergebnis neuer Informationen, Ereignisse futurs ou autres. oder anderweitig. Pour une deion des risques et incertitudes de nature à entraîner une différence entre les résultats réels, les Für eine Beschreibung der Risiken und Unsicherheiten, die tatsächlichen Ergebnisse verursachen könnten einen Unterschied zwischen dem, conditions financières, les performances ou les réalisations de BioAlliance Pharma SA et ceux contenus dans les finanziellen Bedingungen, Leistungen oder Errungenschaften des BioAlliance Pharma SA und die darin enthaltenen in déclarations prospectives, veuillez vous référer à la section « Facteurs de Risque » du Document de Référence Zukunftsgerichtete Aussagen entnehmen Sie bitte dem Abschnitt "Risk Factors" in der Referenz 2009 déposé auprès de l'Autorité des Marchés Financiers, l'AMF, le 29 juin 2010, qui est disponible sur les sites 2009 eingereicht werden bei der AMF, der AMF, 29. Juni 2010, erhältlich auf den Webseiten Internet de l'AMF Der AMF http://www.amf-france.org et de la Société http://www.bioalliancepharma.com. http://www.amf-france.org und Gesellschaft http://www.bioalliancepharma.com. BioAlliance Pharma SA BioAlliance SA Dominique Costantini, CEO Dominique Costantini, CEO Tel.: +33 1 45 58 76 01 Tel.: +33 1 45 58 76 01 dominique.costanti ni@bioalliancepharma.com dominique.costanti ni@bioalliancepharma.com Nicolas Fellmann, CFO Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com nicolas.fellmann @ bioalliancepharma.com ALIZE RP ALIZE RP Caroline Carmagnol Carolina Carmagnol Tel.: +33 6 64 18 99 59 Tel.: +33 6 64 18 99 59 caroline@alizerp.com caroline@alizerp.com
- BioAlliance Pharma SA (Euronext Paris - BIO), ein Unternehmen spezialisiert auf traitement du cancer et aux soins de support, annonce aujourd'hui que M. Gilles Avenard a Krebsbehandlung und unterstützende Pflege, gab heute bekannt, dass Gilles hat Avenard démissionné de son mandat de Membre du Conseil d'administration et Directeur général Rücktritt als Mitglied des Verwaltungsrates und CEO délégué, en charge de la R&D. Delegierter in Gebühr von R & D. Par ailleurs, le Dr Pierre Attali, en charge des Affaires médicales au sein de BioAlliance Darüber hinaus Dr. Pierre Attali, Leiter des Medical Affairs in BioAlliance depuis plusieurs années, est nommé Directeur général délégué. Seit mehreren Jahren war Chief Operating Officer ernannt. «Je me réjouis de la nomination de Pierre Attali. "Ich begrüße die Ernennung von Pierre Attali. Son expérience du développement au Seine Erfahrung in der Entwicklung niveau international, acquise notamment au sein de Synthélabo, et sa pratique hospitalière internationaler Ebene, einschließlich innerhalb Synthelabo erworben und Krankenhaus-Praxis sont des atouts majeurs pour la société et pour ses partenaires commerciaux dans la sind wichtige Trümpfe für das Unternehmen und seine Handelspartner in der préparation des prochains lancements des produits BioAlliance » , déclare Dominique Vorbereitung künftiger Produkteinführungen BioAlliance ", sagte Dominique Costantini, Directeur général de BioAlliance. « Au nom de toute la Société et du Conseil Costantini, CEO von BioAlliance. "Im Namen der Gesellschaft und des Rates d'administration, je remercie chaleureusement Gilles Avenard pour l'esprit pionnier qu'il a su Administration, ich danke Gilles Avenard für den Pioniergeist, hat insuffler à la société en tant que fondateur et dirigeant, pour sa forte contribution et pour la Infusion das Unternehmen als Gründer und Leiter, für seine starken Beitrag und für mise en place des organisations. Entwicklungsorganisationen. Il a apporté tout au long de ces nombreuses années des Er hat in all diesen Jahren viele innovations qui ont permis à la Société de franchir les étapes clés de son développement. Innovationen, die Entwicklung ihrer aktiviert haben, die von Unternehmen zu überqueren den entscheidenden Phasen. Nous lui souhaitons plein succès dans tous ses projets futurs personnels et professionnels» . Wir wünschen ihm viel Erfolg in seinem persönlichen und beruflichen Zukunft. " --------------------------------------------------------------------------------
Page 2 Seite 2
A propos de BioAlliance Pharma Über BioAlliance Spécialisée dans le cancer et les soins de support - pathologies associées à la cancérologie, Spezialisiert auf Krebs und die unterstützende Behandlung - Bedingungen im Zusammenhang mit Krebs, complications de la chimiothérapie et de la radiothérapie et infections opportunistes qui se Komplikationen von Chemo-und Strahlentherapie und opportunistische Infektionen, développent chez les patients immunodéprimés - BioAlliance Pharma conçoit et développe des entwickeln, bei immungeschwächten Patienten - BioAlliance entwirft und entwickelt médicaments innovants essentiellement à visée hospitalière et des médicaments dans des maladies innovative Medikamente in erster Linie nach Krankenhaus und Medikamente bei Krankheiten rares ou orphelines. seltene oder Waise. Créée en 1997 et introduite sur le marché d'Euronext Paris en 2005, la société a Gegründet im Jahr 1997 und notiert an der Euronext Paris im Jahr 2005 das Unternehmen pour ambition de devenir un acteur de référence dans ces domaines, en faisant le lien entre Ehrgeiz, um Felder zu einem führenden Player in dieser, Verknüpfen innovation et besoin des patients. Innovation und Bedürfnisse der Patienten. Elle détient des compétences clés pour identifier, développer et Sie hält den Schlüsselkompetenzen zu identifizieren, weiterzuentwickeln und enregistrer des médicaments en Europe et aux Etats-Unis ; elle confie leur commercialisation à un Shop Arzneimitteln in Europa und den Vereinigten Staaten, vertraute sie einer Marketing réseau de partenaires commerciaux internationaux implantés à l'hôpital. Netzwerk von internationalen Handelspartnern Krankenhaus befindet sich in der. Ses approches ciblées dans des domaines où les besoins médicaux sont insuffisamment satisfaits Seine gezielte Ansätze in Bereichen, in denen medizinische Bedürfnisse erfüllt sind unzureichend contribuent à lutter contre les résistances médicamenteuses et à améliorer la santé et la qualité de vie Beitrag zur Bekämpfung der Resistenz und zur Verbesserung des Lebens Gesundheit und Lebensqualität von des patients. Patienten. BioAlliance Pharma a développé un portefeuille de produits avancés : BioAlliance hat Produkte entwickelt, ein Portfolio von Advanced: Loramyc Loramyc ® ® (Candidose oropharyngée chez les patients immunodéprimés) : Enregistré dans 26 pays (Oropharyngeale Candidiasis bei immungeschwächten Patienten): Aufgenommen in 26 Ländern européens, en Corée et aux Etats-Unis Europa, Korea und den Vereinigten Staaten Setofilm Setofilm ® ® (Prévention et traitement des nausées et vomissements induits par la chimiothérapie et la (Vorbeugung und Behandlung von Übelkeit und Erbrechen infolge von Chemotherapie und radiothérapie et en post-opératoire chez l'adulte et l'enfant) : Enregistré dans 16 pays européens postoperative Strahlentherapie und bei Erwachsenen und Kindern): Länder verzeichneten in 16 europäischen Acyclovir Lauriad Acyclovir Lauriad ® ® (Herpès labial) : Phase III positive (résultats finaux) (Herpes labialis): Positive Phase III (endgültige Ergebnisse) Fentanyl Lauriad Fentanyl Lauriad ® ® (Douleur chronique chez le patient cancéreux) : Résultats cliniques préliminaires (Chronische Schmerzen bei Krebspatienten): erste klinische Ergebnisse positifs de la 1ère Phase I Positive Phase I des ersten AMEP AMEP ® ® (Mélanome invasif) : Phase I (Invasive Melanom): Phase I Clonidine Lauriad Clonidin Lauriad ® ® (Mucite post-chimiothérapie et radiothérapie) : Phase II (Mukositis nach Chemo-und Strahlentherapie): Phase II Doxorubicine Transdrug Doxorubicin Transdrug ® ® (Cancer du foie) : Phase II (Leberkrebs): Phase II Pour plus d'informations, visitez le site de BioAlliance Pharm a à www.bioalliancepharma.com Für weitere Informationen, besuchen Sie BioAlliance Pharm hat www.bioalliancepharma.com Avertissement Warnung Le présent communiqué contient de manière implicite ou expresse certaines déclarations prospectives relatives à Diese Pressemitteilung enthält ausdrückliche oder stillschweigende bestimmte zukunftsbezogene Aussagen in Bezug auf BioAlliance Pharma SA et à son activité. BioAlliance Pharma SA und deren Geschäftstätigkeit betreffen. Ces déclarations dépendent de certains risques connus ou non, Diese Aussagen beinhalten bestimmte bekannte und unbekannte Risiken, d'incertitudes, ainsi que d'autres facteurs, qui pourraient conduire à ce que les résultats réels, les conditions Ungewissheiten und andere Faktoren, die Bedingungen, könnte dazu führen, dass die tatsächlichen Ergebnisse financières, les performances ou réalisations de BioAlliance Pharma SA diffèrent significativement des résultats, Finanz-, Leistungen oder Errungenschaften des BioAlliance Pharma SA erheblich von Ergebnissen, conditions financières, performances ou réalisations exprimés ou sous-entendus dans ces déclarations finanziellen Bedingungen, Leistungen oder Errungenschaften explizit oder implizit in diesen Aussagen prospectives. Interessenten. BioAlliance émet ce communiqué à la présente date et ne s'engage pas à mettre à jour les BioAlliance, die diese Mitteilung ab diesem Datum und verpflichtet sich nicht zur Aktualisierung déclarations prospectives qui y sont contenues, que ce soit par suite de nouvelles informations, événements Zukunftsgerichtete Aussagen darin enthalten ist, ob als Ergebnis neuer Informationen, Ereignisse futurs ou autres. oder anderweitig. Pour une deion des risques et incertitudes de nature à entraîner une différence entre les résultats réels, les Für eine Beschreibung der Risiken und Unsicherheiten, die tatsächlichen Ergebnisse verursachen könnten einen Unterschied zwischen dem, conditions financières, les performances ou les réalisations de BioAlliance Pharma SA et ceux contenus dans les finanziellen Bedingungen, Leistungen oder Errungenschaften des BioAlliance Pharma SA und die darin enthaltenen in déclarations prospectives, veuillez vous référer à la section « Facteurs de Risque » du Document de Référence Zukunftsgerichtete Aussagen entnehmen Sie bitte dem Abschnitt "Risk Factors" in der Referenz 2009 déposé auprès de l'Autorité des Marchés Financiers, l'AMF, le 29 juin 2010, qui est disponible sur les sites 2009 eingereicht werden bei der AMF, der AMF, 29. Juni 2010, erhältlich auf den Webseiten Internet de l'AMF Der AMF http://www.amf-france.org et de la Société http://www.bioalliancepharma.com. http://www.amf-france.org und Gesellschaft http://www.bioalliancepharma.com. BioAlliance Pharma SA BioAlliance SA Dominique Costantini, CEO Dominique Costantini, CEO Tel.: +33 1 45 58 76 01 Tel.: +33 1 45 58 76 01 dominique.costanti ni@bioalliancepharma.com dominique.costanti ni@bioalliancepharma.com Nicolas Fellmann, CFO Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com nicolas.fellmann @ bioalliancepharma.com ALIZE RP ALIZE RP Caroline Carmagnol Carolina Carmagnol Tel.: +33 6 64 18 99 59 Tel.: +33 6 64 18 99 59 caroline@alizerp.com caroline@alizerp.com
24. August 2010
BioAlliance Pharma annonce le lancement d'Oravig® sur le marché américain par son partenaire commercial, Strativa/Par Pharmaceutical BioAlliance kündigt Oravig ® auf dem US-Markt durch seine Handelspartner Strativa / Par Pharmaceutical
www.bioalliancepharma.com
BioAlliance Pharma annonce le lancement d'Oravig® sur le marché américain par son partenaire commercial, Strativa/Par Pharmaceutical BioAlliance kündigt Oravig ® auf dem US-Markt durch seine Handelspartner Strativa / Par Pharmaceutical
www.bioalliancepharma.com
www.bioalliancepharma.com
26 Août 2010 26. August 2010
Dossier d'enregistrement américain d'acyclovir Lauriad® prévu fin 2011 File U. S. Registrierung Acyclovir Lauriad ® geplant für Ende 2011
25 Août 2010 25. August 2010
Résultats du premier semestre 2010 : Un chiffre d'affaires significatif, Un bénéfice semestriel reflétant la valeur des accords de licence mis en place, Une trésorerie nettement renforcée Ergebnisse der ersten Hälfte des Jahres 2010: die einen hohen Umsatz, eine halbe Gewinn, was den Wert von Lizenzvereinbarungen in Ort, eine viel stärkere Cash
BioAlliance Pharma - eine solide Aktie mit enormen Potential
26 Août 2010 26. August 2010
Dossier d'enregistrement américain d'acyclovir Lauriad® prévu fin 2011 File U. S. Registrierung Acyclovir Lauriad ® geplant für Ende 2011
25 Août 2010 25. August 2010
Résultats du premier semestre 2010 : Un chiffre d'affaires significatif, Un bénéfice semestriel reflétant la valeur des accords de licence mis en place, Une trésorerie nettement renforcée Ergebnisse der ersten Hälfte des Jahres 2010: die einen hohen Umsatz, eine halbe Gewinn, was den Wert von Lizenzvereinbarungen in Ort, eine viel stärkere Cash
BioAlliance Pharma - eine solide Aktie mit enormen Potential
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| 0,00 | |
| +0,80 | |
| -1,75 | |
| +0,03 | |
| +0,07 | |
| -0,78 | |
| +0,47 | |
| +3,57 | |
| +0,83 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 173 | ||
| 147 | ||
| 64 | ||
| 54 | ||
| 52 | ||
| 42 | ||
| 37 | ||
| 35 | ||
| 34 | ||
| 31 |
